目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Application
1.2.3. Route of Administration
1.2.4. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. India GLP-1 Receptor Agonist Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis

Chapter 4. India GLP-1 Receptor Agonist Market: Product Business Analysis
4.1. Product Market Share, 2024 & 2030
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Ozempic (semaglutide)
4.4.1. Ozempic (semaglutide) Market, 2018 - 2030 (USD Million)
4.5. Trulicity
4.5.1. Trulicity Market, 2018 - 2030 (USD Million)
4.6. Mounjaro (tirzepatide)
4.6.1. Mounjaro (tirzepatide) Market, 2018 - 2030 (USD Million)
4.7. Wegovy (semaglutide)
4.7.1. Wegovy (semaglutide)Market, 2018 - 2030 (USD Million)
4.8. Rybelsus (oral semaglutide)
4.8.1. Rybelsus (oral semaglutide) Market, 2018 - 2030 (USD Million)
4.9. Saxenda
4.9.1. Saxenda Market, 2018 - 2030 (USD Million)
4.10. Victoza (liraglutide)
4.10.1. Victoza (liraglutide) Market, 2018 - 2030 (USD Million)
4.11. Zepbound
4.11.1. Zepbound Market, 2018 - 2030 (USD Million)
4.12. Others
4.12.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. India GLP-1 Receptor Agonist Market: Application Business Analysis
5.1. Application Market Share, 2024 & 2030
5.2. Application Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Type 2 Diabetes Mellitus
5.4.1. Type 2 Diabetes Mellitus Market, 2018 - 2030 (USD Million)
5.5. Obesity
5.5.1. Obesity Market, 2018 - 2030 (USD Million)

Chapter 6. India GLP-1 Receptor Agonist Market: Route of Administration Business Analysis
6.1. Route of Administration Market Share, 2024 & 2030
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
6.4. Parenteral
6.4.1. Parenteral Market, 2018 - 2030 (USD Million)
6.5. Oral
6.5.1. Oral Market, 2018 - 2030 (USD Million)

Chapter 7. India GLP-1 Receptor Agonist Market: Distribution Channel Business Analysis
7.1. Distribution Channel Market Share, 2024 & 2030
7.2. Distribution Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
7.4. Hospital Pharmacies
7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
7.5. Retail Pharmacies
7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
7.6. Online Pharmacies
7.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. India GLP-1 Receptor Agonist Market: Country Estimates & Trend Analysis
8.1. Country Market Share Analysis, 2024 & 2030
8.2. Country Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
8.4. India
8.4.1. India
8.4.1.1. Key Country Dynamics
8.4.1.2. Target Disease Prevalence
8.4.1.3. Regulatory Framework
8.4.1.4. Reimbursement Framework
8.4.1.5. India GLP-1 Receptor Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. AstraZeneca
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. Novo Nordisk A/S
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. Eli Lilly and Co
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. Biocon
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. Sanofi
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. Glenmark Pharmaceuticals Ltd.
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. Cipla
9.5.7.1. Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. Sun Pharmaceuticals Industries Ltd
9.5.8.1. Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives
9.5.9. Zydus Group
9.5.9.1. Overview
9.5.9.2. Financial Performance
9.5.9.3. Product Benchmarking
9.5.9.4. Strategic Initiatives
9.5.10. Lupin
9.5.10.1. Overview
9.5.10.2. Financial Performance
9.5.10.3. Product Benchmarking
9.5.10.4. Strategic Initiatives
9.5.11. Dr. Reddy’s Laboratories Ltd
9.5.11.1. Overview
9.5.11.2. Financial Performance
9.5.11.3. Product Benchmarking
9.5.11.4. Strategic Initiatives
9.5.12. Alkem
9.5.12.1. Overview
9.5.12.2. Financial Performance
9.5.12.3. Product Benchmarking
9.5.12.4. Strategic Initiatives
9.5.13. Piramal Pharma Limited
9.5.13.1. Overview
9.5.13.2. Financial Performance
9.5.13.3. Product Benchmarking
9.5.13.4. Strategic Initiatives

List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 India GPL-1 receptor agonist market, by region, 2018 - 2030 (USD Million)
Table 4 India GPL-1 receptor agonist market, by product, 2018 - 2030 (USD Million)
Table 5 India GPL-1 receptor agonist market, by application, 2018 - 2030 (USD Million)
Table 6 India GPL-1 receptor agonist market, by route of administration, 2018 - 2030 (USD Million)
Table 7 India GLP-1 receptor agonist market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 India GLP-1 Receptor Agonist market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach and application outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 India GLP-1 Receptor Agonist market dynamics
Fig. 12 India GLP-1 Receptor Agonist market: Porter’s five forces analysis
Fig. 13 India GLP-1 Receptor Agonist market: PESTLE analysis
Fig. 14 Product market, 2018 - 2030 (USD Million)
Fig. 15 Ozempic (semaglutide) market, 2018 - 2030 (USD Million)
Fig. 16 Trulicity market, 2018 - 2030 (USD Million)
Fig. 17 Mounjaro (tirzepatide) market, 2018 - 2030 (USD Million)
Fig. 18 Wegovy (semaglutide) market, 2018 - 2030 (USD Million)
Fig. 19 Rybelsus (oral semaglutide) market, 2018 - 2030 (USD Million)
Fig. 20 Saxenda market, 2018 - 2030 (USD Million)
Fig. 21 Victoza (liraglutide) market, 2018 - 2030 (USD Million)
Fig. 22 Zepbound market, 2018 - 2030 (USD Million)
Fig. 23 Other Products (SOLIQUA (lixisenatide), Bydureon) market, 2018 - 2030 (USD Million)
Fig. 24 Application market, 2018 - 2030 (USD Million)
Fig. 25 Type 2 Diabetes Mellitus market, 2018 - 2030 (USD Million)
Fig. 26 Obesity market, 2018 - 2030 (USD Million)
Fig. 27 Route of administration market, 2018 - 2030 (USD Million)
Fig. 28 Parenteral market, 2018 - 2030 (USD Million)
Fig. 29 Oral market, 2018 - 2030 (USD Million)
Fig. 30 Distribution Channel market, 2018 - 2030 (USD Million)
Fig. 31 Hospital Pharmacies market, 2018 - 2030 (USD Million)
Fig. 32 Retail Pharmacies market, 2018 - 2030 (USD Million)
Fig. 33 Online Pharmacies market, 2018 - 2030 (USD Million)
Fig. 34 India GLP-1 Receptor Agonist market revenue, by region
Fig. 35 Country marketplace: Key takeaways
Fig. 36 India country dynamics
Fig. 37 India GLP-1 receptor agonist market, 2018 - 2030 (USD Million)
Fig. 38 Company categorization
Fig. 39 Company market position analysis
Fig. 40 Strategic framework